Definitive Healthcare (DH) Projected to Announce Earnings on Thursday

Definitive Healthcare (NASDAQ:DH) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $54.57 million for the quarter. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The business had revenue of $55.20 million during the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%. On average, analysts expect Definitive Healthcare to post $0.06 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

Definitive Healthcare Trading Up 3.2%

NASDAQ:DH opened at $1.14 on Thursday. The firm has a market capitalization of $121.69 million, a price-to-earnings ratio of -0.71, a price-to-earnings-growth ratio of 13.33 and a beta of 1.40. Definitive Healthcare has a one year low of $0.61 and a one year high of $3.00. The business has a fifty day moving average price of $0.96 and a 200-day moving average price of $1.11. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DH shares. Morgan Stanley reduced their price target on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $1.00 price target on shares of Definitive Healthcare in a report on Wednesday, August 12th. Finally, BTIG Research restated a “neutral” rating on shares of Definitive Healthcare in a research note on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $1.47.

About Definitive Healthcare

Definitive Healthcare Corp. (NASDAQ: DH) provides data, analytics and commercial intelligence solutions for the healthcare industry. Its platform is designed to help organizations understand healthcare markets, identify business opportunities and make data-driven decisions.

The company serves pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, hospitals and health systems, and other healthcare services organizations. Its offerings include information on healthcare providers and organizations, market intelligence, sales and marketing analytics, clinical trial insights, and tools that support commercial planning, market access and customer engagement.

Definitive Healthcare was founded in 2011 and became a publicly traded company in 2021.